<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">NPJ Vaccines</journal-id><journal-id journal-id-type="iso-abbrev">NPJ Vaccines</journal-id><journal-id journal-id-type="pmc-domain-id">3297</journal-id><journal-id journal-id-type="pmc-domain">npjvac</journal-id><journal-title-group><journal-title>NPJ Vaccines</journal-title></journal-title-group><issn pub-type="epub">2059-0105</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7930017</article-id><article-id pub-id-type="pmcid-ver">PMC7930017.1</article-id><article-id pub-id-type="pmcaid">7930017</article-id><article-id pub-id-type="pmcaiid">7930017</article-id><article-id pub-id-type="pmid">33658522</article-id><article-id pub-id-type="doi">10.1038/s41541-021-00294-8</article-id><article-id pub-id-type="publisher-id">294</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Vaccines for human fungal diseases: close but still a long way to go</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1762-0076</contrib-id><name name-style="western"><surname>Oliveira</surname><given-names initials="LVN">Lorena V. N.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3638-4582</contrib-id><name name-style="western"><surname>Wang</surname><given-names initials="R">Ruiying</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-5749-3112</contrib-id><name name-style="western"><surname>Specht</surname><given-names initials="CA">Charles A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-3799-3064</contrib-id><name name-style="western"><surname>Levitz</surname><given-names initials="SM">Stuart M.</given-names></name><address><email>stuart.levitz@umassmed.edu</email></address><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.168645.8</institution-id><institution-id institution-id-type="ISNI">0000 0001 0742 0364</institution-id><institution>Department of Medicine, </institution><institution>University of Massachusetts Medical School, </institution></institution-wrap>Worcester, MA USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>3</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>6</volume><issue-id pub-id-type="pmc-issue-id">372033</issue-id><elocation-id>33</elocation-id><history><date date-type="received"><day>29</day><month>11</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>1</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>03</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>19</day><month>03</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-03-20 00:17:24.047"><day>20</day><month>03</month><year>2021</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2021</copyright-statement><license license-type="OpenAccess"><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="41541_2021_Article_294.pdf"/><abstract id="Abs1"><p id="Par1">Despite the substantial global burden of human fungal infections, there are no approved fungal vaccines to protect at risk individuals. Here, we review the progress that has been made and the challenges that lie ahead in the quest towards efficacious fungal vaccines. In mouse studies, protection has been achieved with vaccines directed against fungal pathogens, including species of <italic toggle="yes">Candida, Cryptococcus</italic>, and <italic toggle="yes">Aspergillus</italic>, that most commonly cause life-threatening human disease. Encouraging results have been obtained with vaccines composed of live-attenuated and killed fungi, crude extracts, recombinant subunit formulations, and nucleic acid vaccines. Novel adjuvants that instruct the immune system to mount the types of protective responses needed to fight mycotic infections are under development. Candidate vaccines include those that target common antigens expressed on multiple genera of fungi thereby protecting against a broad range of mycoses. Encouragingly, three vaccines have reached human clinical trials. Still, formidable obstacles must be overcome before we will have fungal vaccines licensed for human use.</p></abstract><kwd-group kwd-group-type="npg-subject"><title>Subject terms</title><kwd>Diseases</kwd><kwd>Immunology</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/100006492</institution-id><institution>Division of Intramural Research, National Institute of Allergy and Infectious Diseases (Division of Intramural Research of the NIAID)</institution></institution-wrap></funding-source><award-id>AI125045</award-id><principal-award-recipient><name name-style="western"><surname>Specht</surname><given-names>Charles A.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; The Author(s) 2021</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par2">The global burden of serious fungal diseases is increasing as a direct consequence of the burgeoning number of immunocompromised persons<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. Risk factors for invasive fungal infections include infection with the human immunodeficiency virus (HIV), immunosuppressive therapy to prevent organ transplant rejection, biological immunomodulatory agents to treat autoimmune diseases, bone marrow suppressing cancer chemotherapies, indwelling devices such as intravenous catheters, and long-term hospitalization, especially with receipt of broad-spectrum antibiotics<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR2">2</xref></sup>. Even with the availability of antifungal drugs, the burden of life-threatening fungal infections is thought to exceed one million deaths annually, although numbers are difficult to estimate due in part to inadequate availability of diagnostic tests and disease reporting<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR4">4</xref></sup>. Superficial mycoses, such as dermatophytic infections of the skin and nails, affect more than 25% of the population worldwide, although they are generally treatable<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. The annual medical cost of fungal diseases is estimated to exceed 7.2 billion dollars in the United States alone<sup><xref ref-type="bibr" rid="CR5">5</xref></sup>.</p><p id="Par3">The substantial morbidity and mortality rates highlight the relevance of developing effective vaccines to control fungal pathogens. Despite efforts, unfortunately, there are no licensed vaccines available to prevent and control human invasive fungal infections. In this review, we outline the advances and challenges toward the development of fungal vaccines, providing examples of potential targets and promising vaccine strategies.</p><sec id="Sec2"><title>Challenges and efforts toward developing fungal vaccines</title><p id="Par4">Vaccines are considered one of the greatest achievements in medicine<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. For example, their use led to eradication of smallpox, and substantially reduced poliomyelitis, measles, diphtheria, and pneumococcal infections<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. Additionally, according to the World Health Organization (WHO), vaccines are being successfully used against more than 25 debilitating or life-threatening diseases, including tetanus, rabies, influenza, meningitis, cholera, rubella, and hepatitis B.</p><p id="Par5">For protection against communicable diseases, vaccines are among the most cost-effective measures available. Vaccines for many infectious diseases, including invasive mycoses, however, are not available<sup><xref ref-type="bibr" rid="CR6">6</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup>. Fungal diseases often have a poor prognosis stemming in part from the limited arsenal of antifungal drugs compounded by the increasing occurrence of antifungal resistance<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. The lack of reliable diagnostics for many fungal diseases can lead to delays in treatment<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Given that, worldwide efforts are being made to develop vaccines against fungal pathogens<sup><xref ref-type="bibr" rid="CR2">2</xref>,<xref ref-type="bibr" rid="CR8">8</xref>,<xref ref-type="bibr" rid="CR10">10</xref>,<xref ref-type="bibr" rid="CR11">11</xref></sup>. Still, formidable challenges remain, many of which, along with their potential solutions, are listed in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Challenges associated with fungal vaccine development.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Challenges</th><th colspan="1" rowspan="1">Potential solutions</th></tr></thead><tbody><tr><td rowspan="4" colspan="1">Population most at risk is immunosuppressed</td><td colspan="1" rowspan="1">Vaccinate prior to anticipated immunosuppression.</td></tr><tr><td colspan="1" rowspan="1">Augment specific immune system responses less affected by immunosuppression.</td></tr><tr><td colspan="1" rowspan="1">Transfer protective lymphocytes to patient.</td></tr><tr><td colspan="1" rowspan="1">Improve adjuvants.</td></tr><tr><td colspan="1" rowspan="1">Diverse infection sites in the host</td><td colspan="1" rowspan="1">Utilize delivery systems or adjuvants that drive the immune response at multiple sites of infections.</td></tr><tr><td colspan="1" rowspan="1">Intraspecies and interspecies antigenic variation among fungi</td><td colspan="1" rowspan="1">Target multiple epitopes with multivalent vaccines.</td></tr><tr><td rowspan="2" colspan="1">Similarities between Fungi and Animalia kingdoms</td><td colspan="1" rowspan="1">Target structures existing only in fungi, such as the cell wall.</td></tr><tr><td colspan="1" rowspan="1">Use protein antigens unique to fungi to minimize autoimmune responses.</td></tr><tr><td rowspan="2" colspan="1">Translation from animal models to humans</td><td colspan="1" rowspan="1">Test the candidate vaccine in multiple animal models.</td></tr><tr><td colspan="1" rowspan="1">Perform ex vivo studies with human cells.</td></tr><tr><td colspan="1" rowspan="1">Formulation</td><td colspan="1" rowspan="1">Select a delivery system and/or adjuvants to optimize protective responses and safety.</td></tr><tr><td colspan="1" rowspan="1">Commercialization</td><td colspan="1" rowspan="1">Attract interest and investments from governmental agencies, non-governmental organizations, and biopharmaceutical companies.</td></tr></tbody></table></table-wrap></p><p id="Par6">As mentioned, the immunocompromised population is at highest risk for serious fungal infections. However, immunological impairment poses challenges with respect to both the efficacy and safety of vaccines. In this regard, the high immunogenicity of live vaccines makes them perhaps most likely to elicit protective responses, but must be used with caution because of the potential risk for infections from the vaccine itself. On the other hand, inactivated whole organism and subunit vaccines are safer; however, immunocompromised individuals are less likely to respond to vaccination due to their debilitated immune status<sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Efforts are being made to improve adjuvants and vaccine formulations to elicit stronger protective responses, and to target those immune response pathways that may not be compromised<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Another potential solution is vaccinating individuals prior to their anticipated immunosuppression when the immune system is still functionally effective. Examples include persons awaiting solid organ transplantation and individuals with HIV infection, who have relatively high CD4<sup>+</sup> T cell counts.</p><p id="Par7">An additional challenge to developing a vaccine is translating preclinical studies in animals to humans. Most in vivo vaccine studies are initially conducted in inbred mice, as they are relatively inexpensive and have a well-defined immune system. However, inherent differences in murine and human immune responses are still a concern and caution needs to be taken with regard to extrapolating efficacy data across species<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. Even with the attempt to reproduce aspects of human disease, inbred mice lack genetic diversity. Moreover, laboratory mice are generally housed under conditions whereby they have limited exposure to environmental fungi, such as airborne spores and thus may not be exposed to fungal antigens commonly encountered in the &#8220;real world&#8221;. To minimize these drawbacks, prior to clinical studies, vaccine candidates ideally should be tested in multiple animal models.</p><p id="Par8">Reactogenicity and safety must be investigated in pre-clinical models as a prerequisite to clinical trials<sup><xref ref-type="bibr" rid="CR14">14</xref></sup>. At this point, converting a vaccine candidate into one approved for use in humans entails financing clinical trials and product manufacture. For those fungal infections that mostly affect populations living in resource-limited areas, the interest of pharmaceutical companies may be limited and vaccine commercialization could require attracting investments of governmental and non-governmental organizations<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>. That said, fungal pathogens are a major public health concern worthy of global attention, and funding incentives for preventive fungal vaccines are urgently needed.</p></sec><sec id="Sec3"><title>Fungal cell wall structure</title><p id="Par9">Fungi and animals are phylogenetically grouped in the same Eukaryotic domain<sup><xref ref-type="bibr" rid="CR15">15</xref></sup>. Then not surprisingly, many similarities exist between fungal and human cells; these become important considerations for drug discovery and treatment of fungal diseases. A major difference between the Fungi and Animalia kingdoms is the presence of the cell wall on almost all fungal cells<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Consequently, the proteins that synthesize and remodel the cell wall are important drug targets. Moreover, fungal cell wall components are recognized by the innate immune system in humans<sup><xref ref-type="bibr" rid="CR17">17</xref>,<xref ref-type="bibr" rid="CR18">18</xref></sup>, leading to adaptive and trained immune responses. As discussed below, an area of research is exploiting this response in vaccine development.</p><p id="Par10">The cell wall is composed mainly of conserved crosslinked carbohydrate polymers and mannoproteins that are recognized by pattern recognition receptors on immune cells of the host, notably monocytes, macrophages, and dendritic cells<sup><xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref></sup>. The most abundant components of the fungal cell wall are mannoproteins and &#946;-glucans, followed by chitin/chitosan. Mannoproteins are predominately found in the outer portion of cell wall, &#946;-glucans tends to be in the middle, while chitin/chitosan trends towards the inner portion of the cell wall. These constituents of the cell wall are found in practically all invasive fungal pathogens (reviewed in the refs. <sup><xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR21">21</xref></sup>). An overview of the fungal cell wall components is provided in Table <xref rid="Tab2" ref-type="table">2</xref> and Fig. <xref rid="Fig1" ref-type="fig">1</xref>.<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Major components of fungal cell walls.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Fungal cell wall components</th><th colspan="1" rowspan="1">Structure composition</th><th colspan="1" rowspan="1">Location</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Chitin</td><td colspan="1" rowspan="1">Homopolymer of N-Acetylglucosamine that provides structural stability</td><td colspan="1" rowspan="1">Inner portion of cell wall, adjacent to the plasma membrane</td></tr><tr><td colspan="1" rowspan="1">Chitosan</td><td colspan="1" rowspan="1">Deacetylated chitin</td><td colspan="1" rowspan="1">Inner portion of cell wall, intermingled with chitin</td></tr><tr><td colspan="1" rowspan="1">&#946;-glucan</td><td colspan="1" rowspan="1">Homopolymers of glucose with &#946;-1,3-glucans forming the scaffold and &#946;-1,6-glucans forming the branches</td><td colspan="1" rowspan="1">Middle portion of cell wall, between chitin and mannans</td></tr><tr><td colspan="1" rowspan="1">Mannoprotein</td><td colspan="1" rowspan="1">Mannose chains of varying lengths and configurations added to fungal proteins via N-linkages or O-linkages</td><td colspan="1" rowspan="1">From anchorage in plasma membrane to outer portion of cell wall</td></tr></tbody></table></table-wrap><fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><title>Schematic model of the fungal cell wall.</title><p>This model shows the three basic components of the cell wall present in almost all fungal pathogens. Mannoproteins have polymers of mannose that decorate the proteins through O-linkages or N-linkages and are predominately found in the outer portion of cell wall. &#946;-glucans are the most abundant constituent of the cell wall and tend to be in the middle with &#946;-1,3-glucans forming the scaffold and &#946;-1,6-glucans forming the branches, while chitin is found in the inner portion of the cell wall and linked to &#946;-1,3-glucan. Other components of the cell wall in some fungi include &#945;-glucan, galactomannan, chitosan, and melanin. In addition, the cryptococcal capsule is linked to the cell wall. Figure created with BioRender.com.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e565" position="float" orientation="portrait" xlink:href="41541_2021_294_Fig1_HTML.jpg"/></fig></p><p id="Par11">Some fungal cell walls also contain galactomannan, &#945;-glucan and melanin<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>. In addition, it is important to highlight the presence of a polysaccharide capsule on <italic toggle="yes">Cryptococcus</italic> spp., composed primarily of glucuronoxylomannan (GXM) and galactoxylomannan; the capsule is a dominant virulence factor<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>. Structurally, the capsule envelops the cell wall and, among its several roles, &#8220;masks&#8221; recognition of cell wall ligands by pattern recognition receptors thus interfering with the development of immunity<sup><xref ref-type="bibr" rid="CR16">16</xref></sup>. Finally, fungi release extracellular vesicles containing proteins, lipids, and nucleic acids. In addition to secretion into the extracellular milieu, extracellular vesicles may traffic to the cell wall and contribute to cell wall remodeling and enable surface expression of proteins<sup><xref ref-type="bibr" rid="CR23">23</xref></sup>.</p><p id="Par12">Compounding the challenges encountered by interspecies differences in the fungal cell wall structure, the host faces dynamic changes in the distribution and amount of fungal cell wall components that accompany morphological changes during infection. External stress events, transition between yeast and hyphal growth, and the process of cellular division can impact the cell wall to decrease host recognition, impair inflammatory responses, and increase fungal virulence<sup><xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR24">24</xref></sup>.</p></sec><sec id="Sec4"><title>Fungal vaccine categories and adjuvants</title><p id="Par13">Fungal vaccines can be divided into several broad categories based upon their composition, ranging from multiple to single antigens: whole organism vaccines (live-attenuated or killed fungal cells), crude extracts (fractions derived from cells and medium of fungal cultures), purified subunit vaccines (proteins, peptides), and nucleic acids (RNA and DNA) encoding the antigen(s) of interest (Table <xref rid="Tab3" ref-type="table">3</xref>). Approaches using dendritic cells pulsed ex vivo with antigen(s) are not practical for routine immunizations, but have potential for use in therapeutic vaccines for patients with refractory diseases<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>. As discussed above, whole organism vaccines generally have strong immunogenicity but often at the cost of increased side effects, including risk of infection when live-attenuated vaccines are given to immunocompromised populations. Thus, many investigators have focused on identifying antigens which, either in native or recombinant form, can be used in subunit fungal vaccines.<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Overview of the advantages and disadvantages of the major fungal vaccine categories.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1">Vaccine Category</th><th colspan="1" rowspan="1">Advantages</th><th colspan="1" rowspan="1">Disadvantages</th><th colspan="1" rowspan="1">Representative vaccines</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Live-attenuated</td><td colspan="1" rowspan="1">Strong and long-lasting immunogenicity; manufacturing processes are straightforward</td><td colspan="1" rowspan="1">Risk of sustained infection in immunocompromised population; reactogenicity; autoimmunity</td><td colspan="1" rowspan="1">Mutant <italic toggle="yes">C. neoformans</italic> strain lacking the enzyme sterylglucosidase 1<sup><xref ref-type="bibr" rid="CR59">59</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Killed fungus</td><td colspan="1" rowspan="1">Cannot cause infection; stabler than live-attenuated vaccines; manufacturing processes are straightforward</td><td colspan="1" rowspan="1">Elicit less strong immune responses compared to live vaccines; reactogenicity; autoimmunity</td><td colspan="1" rowspan="1">Formalin-killed spherule vaccine for coccidioidomycosis<sup><xref ref-type="bibr" rid="CR75">75</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Fungal extracts</td><td colspan="1" rowspan="1">Contain numerous multivalent antigens</td><td colspan="1" rowspan="1">Reactogenicity; autoimmunity</td><td colspan="1" rowspan="1">Glucan particles containing <italic toggle="yes">Cryptococcus</italic> alkaline extracts<sup><xref ref-type="bibr" rid="CR53">53</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Purified proteins, peptides, carbohydrates, and lipids</td><td colspan="1" rowspan="1">Fewer antigens minimizes the potential side effects</td><td colspan="1" rowspan="1">Narrow immune response due to fewer antigens; adjuvants are needed; careful epitope selection, antigen design and purification are required</td><td colspan="1" rowspan="1">NDV-3A vaccine (containing the recombinant N-terminus of <italic toggle="yes">C. albicans</italic> agglutinin-like sequence 3 protein)<sup><xref ref-type="bibr" rid="CR44">44</xref></sup></td></tr><tr><td colspan="1" rowspan="1">Nucleic acid-encoded delivery of antigen(s): DNA or RNA vaccine</td><td colspan="1" rowspan="1">Fast manufacturing process; strong immune responses</td><td colspan="1" rowspan="1">Risks of eliciting unintended immune reactions; strict temperature requirements for storage</td><td colspan="1" rowspan="1">DNA vaccine encoding cell wall antigen Mp1p against <italic toggle="yes">Penicillium marneffei</italic> infection<sup><xref ref-type="bibr" rid="CR81">81</xref></sup></td></tr></tbody></table></table-wrap></p><p id="Par14">Subunit vaccines require adjuvants, compounds which enhance antigen immunogenicity by promoting adaptive immune responses. Most vaccines in clinical use mediate antibody-dependent protection via mechanisms that include opsonophagocytosis and neutralization of viruses and toxins. Traditional adjuvants which promote antibody responses, particularly alum, have been effective for these purposes. However, because CD4<sup>+</sup> T helper cell (Th)-mediated immunity is paramount for defending against many mycoses, adjuvants which elicit strong Th1 or Th17 cell-mediated responses have been proposed for inclusion in fungal vaccines<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Some adjuvants used in experimental models to stimulate Th responses, such as complete Freunds adjuvant, are too toxic for routine use in humans but may be useful in experimental vaccine studies to demonstrate proof of principle<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. Other adjuvants, such as CpG oligodeoxynucleotides, may be more translationally relevant as they have been used in human vaccines<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>.</p><p id="Par15">We and others have proposed exploiting components of fungal cell walls, such as &#946;-1,3-glucans and mannans, as adjuvants, reasoning that the immune response generated will mimic the type of protective immune response seen in natural infection<sup><xref ref-type="bibr" rid="CR18">18</xref></sup>. One such approach has been to package fungal antigens into glucan particles (GPs). GPs are hollow, porous yeast cell wall shells manufactured from <italic toggle="yes">Saccharomyces cerevisiae</italic>, and primarily composed of &#946;-1,3-glucan<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. GPs are recognized by Dectin-1 and are also potent activators of the complement pathway<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>. Mice immunized with GPs loaded with the model antigen ovalbumin developed long-lasting antigen-specific antibody and Th1-biased and Th17-biased CD4<sup>+</sup> T cell responses<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Mice vaccinated with GPs formulated with fungal antigens were protected following challenges with a range of fungal pathogens<sup><xref ref-type="bibr" rid="CR30">30</xref>&#8211;<xref ref-type="bibr" rid="CR33">33</xref></sup>. Using a related approach, protective vaccines consisting of <italic toggle="yes">Coccidioides</italic> and <italic toggle="yes">Blastomyces</italic> antigens packaged into glucan-chitin particles (GCP) have been described<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. GCPs are similar to GPs except they are produced from the yeast <italic toggle="yes">Rhodotorula mucilaginosa</italic> and contain extra chitin in their cell walls.</p></sec><sec id="Sec5"><title>Potential fungal vaccines</title><p id="Par16"><italic toggle="yes">Candida, Cryptococcus, Aspergillus</italic>, and <italic toggle="yes">Pneumocystis</italic> are the most common fungal genera causing invasive human infections. Endemic dimorphic fungi, such as <italic toggle="yes">Histoplasma</italic>, <italic toggle="yes">Coccidioides</italic>, <italic toggle="yes">Paracoccidioides</italic>, and <italic toggle="yes">Blastomyces</italic> also cause invasive mycosis<sup><xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref></sup>. Examples of the disparate morphologies of fungi in human tissue are shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. Other fungi that cause serious infections include species of <italic toggle="yes">Mucor</italic>, <italic toggle="yes">Sporothrix</italic>, <italic toggle="yes">Scedosporium</italic>, and <italic toggle="yes">Fusarium</italic><sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. However, for these and other relatively rare fungi, clinical testing of pathogen-specific vaccines presents obvious logistical difficulties. In this section, we review vaccine candidates against the fungal genera responsible for most cases of invasive mycoses.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><title>Examples of the diversity in fungal morphology in human tissue from patients with mycoses.</title><p><bold>a</bold> Tissue Gram stain of <italic toggle="yes">C. albicans</italic> from a patient with endocarditis. Hyphae (elongated cells), pseudo-hyphae (sausage-shaped cells) and yeasts (oval cells, some with buds) stain deep purple. <italic toggle="yes">Candida</italic> cells average 2&#8211;8 microns in diameter. <bold>b</bold> Mucicarmine stain of <italic toggle="yes">C. neoformans</italic> in the lungs of a patient with pulmonary cryptococcosis. Budding yeast cells with capsules that stain rose red are present. Yeast cells average about 5 microns in diameter without capsule. Capsular thickness is variable, typically ranging from 1 to 10 microns. <bold>c</bold> Grocott&#8217;s methenamine silver stain of <italic toggle="yes">A. fumigatus</italic> from a patient with invasive pulmonary aspergillosis. Septate hyphae with &#8220;Y&#8221;-shaped branching that stain silvery black are present. Average hyphal diameter is about 3 microns. <bold>d</bold> Periodic acid-Schiff stain of <italic toggle="yes">C. immitis</italic> from a patient with coccidioidomycosis. Three spherules, each containing endospores, are present. Spherules and endospores range in diameter from 10 to 100 microns and 2 to 5 microns, respectively. A single spherule can contain hundreds of endospores. Photo image credits. <bold>a</bold>, <bold>b</bold>, and <bold>d</bold>: Centers for Disease Control Public Health Image Library. <bold>c</bold><bold>:</bold> Wikimedia Commons.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d32e890" position="float" orientation="portrait" xlink:href="41541_2021_294_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec6"><title><italic toggle="yes">Candida</italic> sp.</title><p id="Par17"><italic toggle="yes">Candida</italic> species commonly colonize humans as commensal organisms; however, in situations of immunosuppression they can opportunistically become pathogens. <italic toggle="yes">Candida albicans</italic> and non-<italic toggle="yes">albicans</italic> species are the most common cause of life-threatening invasive fungal infections<sup><xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR35">35</xref></sup>. Globally, an estimated 700,000 persons a year suffer from invasive candidiasis<sup><xref ref-type="bibr" rid="CR4">4</xref></sup>, with an associated mortality that may exceed 50%<sup><xref ref-type="bibr" rid="CR3">3</xref></sup>. Furthermore, <italic toggle="yes">Candida</italic> can also cause mucocutaneous infections, such as vulvovaginal candidiasis which, while rarely lethal, are associated with significant morbidity<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>. For example, vulvovaginal candidiasis can have a profoundly negative impact on quality-of-life. It is estimated that the majority of women experience vulvovaginal candidiasis at least once in their lifetime and many women suffer from recurrent disease<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>. Importantly, the emergence of drug resistant strains, such as <italic toggle="yes">C. auris</italic>, is a public health concern. Thus, the need for new therapies and protective vaccines against <italic toggle="yes">Candida</italic> has increased.</p><p id="Par18">With mouse models of vulvovaginal and/or systemic candidiasis, the efficacy of anti-<italic toggle="yes">Candida</italic> vaccines has been demonstrated targeting virulence factors, and <italic toggle="yes">Candida</italic> virulent forms such as hyphae and cell wall antigens, with a variety of formulations, including live attenuated (generally strains with impaired yeast-hyphae conversion<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>); recombinant proteins (using surface-located or adhesion proteins<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref></sup>); cell wall extracts, extracellular vesicles<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>, and glycoconjugates<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>. However, morphological, phenotypic, and genetic variability among <italic toggle="yes">Candida</italic> species poses a challenge to vaccine development. In addition, as <italic toggle="yes">Candida</italic> is a common human commensal, there is a theoretical concern that <italic toggle="yes">Candida</italic> vaccines could disrupt the normal microbiota. Targeting antigens specific to the invasive hyphal form could minimize this potential drawback. On the host side, the diverse infection sites and the different kinds of immune deficiencies in at-risk groups are obstacles for designing a vaccine that broadly protects this wide clinical spectrum of disease<sup><xref ref-type="bibr" rid="CR9">9</xref></sup>.</p><p id="Par19">Two recombinant <italic toggle="yes">Candida</italic> vaccines have reached human clinical testing with promising results. The first, named PEV7, consists of recombinant aspartyl-proteinase 2 (Sap2), a secreted protein of <italic toggle="yes">C. albicans</italic>, assembled into virosomes<sup><xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR42">42</xref></sup>. After protection was demonstrated in <italic toggle="yes">C. albicans</italic>-challenged rats, a phase 1 clinical trial was conducted to assess the safety and immunogenicity of PEV7 in healthy female volunteers. All of the 48 vaccinated women developed specific B-cell memory responses (ClinicalTrials.gov identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01067131">NCT01067131</ext-link>)<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p><p id="Par20">The second vaccine, NDV-3, contains the recombinant N-terminus of <italic toggle="yes">C. albicans</italic> agglutinin-like sequence 3 protein (Als3p, a cell surface adhesin and invasin) formulated with aluminum hydroxide adjuvant<sup><xref ref-type="bibr" rid="CR39">39</xref>,<xref ref-type="bibr" rid="CR43">43</xref></sup>. Preclinical studies demonstrated the vaccine was immunogenic and protected mice from <italic toggle="yes">Candida</italic> species. Interestingly, mice were also protected following challenge with <italic toggle="yes">Staphylococcus aureus</italic>, apparently due to structural homology between Als3p and surface proteins on <italic toggle="yes">S. aureus</italic>. In a phase 1 clinical trial which recruited 40 volunteers, NDV-3 elicited increased antigen-specific IgG and IgA1 titers as well as increased IFN-&#947; and IL-17A cytokine production compared to placebo recipients (ClinicalTrials.gov identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01273922">NCT01273922</ext-link>)<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Based on these data and a favorable safety profile, a multicenter double-blind placebo-controlled phase 1b/2a trial was undertaken to assess the immunogenicity and efficacy of the NDV-3A vaccine in 188 women with recurrent vulvovaginal candidiasis (RVVC)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. NDV-3A is identical to NDV-3 except it lacks a 6-His tag and linker sequences. As with NDV-3, NDV-3A was safe and highly immunogenic. There were no statistically significant differences between treatment and placebo groups in the primary efficacy analysis. However, in a post-hoc subgroup analysis, subjects aged &lt;40 years had significantly fewer RVVC episodes during the 12-month study period (ClinicalTrials.gov identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT01926028">NCT01926028</ext-link>)<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>.</p><p id="Par21">Women with RVVC represent a logical population for <italic toggle="yes">Candida</italic> vaccine studies because the incidence of recurrence is high and therefore vaccine efficacy can be determined without having to enroll inordinately large numbers of subjects in clinical trials. But it should be appreciated that in many women, RVVC is thought to be due to an overly exuberant inflammatory response to <italic toggle="yes">Candida</italic> and therefore therapeutic vaccines have the potential to worsen disease<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Studies to determine whether vaccines can prevent invasive candidiasis would likely need to enroll thousands of patients given the relatively low incidence even in the higher risk populations.</p><p id="Par22">PEV7 and NDV-3A vaccines each were formulated with a single protein antigen. Given intraspecies and interspecies antigenic variation, including differences between yeast and hyphal forms, many investigators aim to develop multivalent <italic toggle="yes">Candida</italic> vaccines that would provide enhanced protection. This tactic has the potential to expand the protective range of the immune response, while decreasing the ability of <italic toggle="yes">Candida</italic> to evade host immunity<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Approaches include combining known immunogenic antigens and using in silico analysis to identify immunodominant <italic toggle="yes">Candida</italic> antigens<sup><xref ref-type="bibr" rid="CR45">45</xref>,<xref ref-type="bibr" rid="CR46">46</xref></sup>.</p></sec><sec id="Sec7"><title><italic toggle="yes">Cryptococcus</italic> sp.</title><p id="Par23">The species complexes of <italic toggle="yes">Cryptococcus neoformans</italic> and <italic toggle="yes">C. gattii</italic> cause cryptococcosis. Infection is thought to most commonly start after pulmonary inhalation; subsequent dissemination to other organ systems, particularly the central nervous system, can ensue. Persons with compromised T cell immunity are particularly susceptible. Annually, more than 220,000 cryptococcal meningitis cases in HIV-infected persons are estimated to occur worldwide, with about 180,000 deaths<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. <italic toggle="yes">Cryptococcus</italic> is unique among the medically important fungi in being encapsulated; this presents opportunities and challenges in terms of vaccine development. Its polysaccharide capsule, which consists mainly of GXM, is poorly immunogenic. To improve the antigenicity of GXM, a vaccine containing GXM conjugated to tetanus toxoid was developed; immunized mice developed antibodies against GXM and were partially protected following challenge with <italic toggle="yes">C. neoformans</italic><sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Similarly, a conjugated peptide mimetic of GXM elicited protective antibodies<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>.</p><p id="Par24">Other groups have focused on discovering protein antigens that stimulate T cell responses for inclusion in subunit vaccines. Vaccines containing crude fractions isolated from acapsular and encapsulated cryptococcal strains by a variety of techniques, including concanavalin A binding (to enrich for mannoproteins)<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>, molecular sizing<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>, alkaline extraction<sup><xref ref-type="bibr" rid="CR52">52</xref></sup>, cellular fractionation<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>, and purification of extracellular vesicles<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>, provided some degree of protection against challenge with <italic toggle="yes">C. neoformans</italic> and <italic toggle="yes">C. gattii</italic>. More recent work has sought to discover individual antigenic proteins which protect in mouse models of cryptococcosis. Using biased and unbiased selection, our laboratory has identified 11 proteins which, when recombinantly expressed and delivered in glucan particles, protect BALB/c and/or C57BL/6 mice against an otherwise lethal infection<sup><xref ref-type="bibr" rid="CR32">32</xref>,<xref ref-type="bibr" rid="CR55">55</xref></sup>.</p><p id="Par25">Several live-attenuated and heat-killed cryptococcal mutant strains have been proposed as vaccine candidates based on encouraging protection data. Pulmonary administration of an avirulent chitosan-deficient strain, constructed by deleting three chitin deacetylase genes, conferred full protection against a subsequent <italic toggle="yes">C. neoformans</italic> lethal infection. The vaccine elicited a protective Th1-type adaptive immune response and was effective even when heat-killed<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>. Mice were also protected from otherwise lethal challenge with mutant <italic toggle="yes">C. neoformans</italic> vaccine strains: 1) overexpressing the transcription factor, Znf2<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>; 2) lacking sterylglucosidase, which results in accumulation of the glycolipid, sterylglucoside, in the cell membrane<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>; and 3) lacking the F-box protein Fbp1<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p><p id="Par26">Two whole organism <italic toggle="yes">Cryptococcus</italic> vaccine approaches that provide proofs of principle, albeit with limited direct translation relevance, are worth noting. In the first, a <italic toggle="yes">C. neoformans</italic> strain was genetically engineered to express murine IFN-&#947;. Mice vaccinated with this strain were fully protected from subsequent challenge with a highly virulent strain by mechanisms dependent on STAT1 signaling and induction of trained immunity of dendritic cells<sup><xref ref-type="bibr" rid="CR60">60</xref>,<xref ref-type="bibr" rid="CR61">61</xref></sup>. In the second approach, bone marrow-derived dendritic cells were pulsed with heat-killed acapsular <italic toggle="yes">C. gattii</italic> cells and then injected intravenously into mice. The vaccine induced lung-resident memory Th17 cells and conferred protection upon recipient mice challenged with a virulent <italic toggle="yes">C. gattii</italic> strain<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>.</p><p id="Par27">Finally, although closely related, the species complexes of <italic toggle="yes">C. neoformans</italic> and <italic toggle="yes">C. gattii</italic> cause infections with distinct clinical manifestations. The species elicit divergent immune responses<sup><xref ref-type="bibr" rid="CR62">62</xref></sup> and differ in terms of the proteome expressed during infection. Ideally, candidate vaccines able to protect against both species should be prioritized for advancement to human testing. However, for areas such as British Columbia, Canada, where hypervirulent strains of <italic toggle="yes">C. gattii</italic> are endemic, it may be practical to develop a species-specific vaccine to protect the population.</p></sec><sec id="Sec8"><title><italic toggle="yes">Aspergillus</italic> sp.</title><p id="Par28"><italic toggle="yes">Aspergillus</italic> is a globally ubiquitous filamentous fungus, widely present in soil and decaying vegetation. Airborne spores (conidia) are regularly inhaled and are typically contained by host defenses without being harmful. However, in at risk immunosuppressed individuals, germination of conidia into tissue invasive hyphae can cause a range of acute to chronic diseases. Persons most at risk include those with neutropenia, recipients of stem cell and solid organ transplants, and those receiving immunosuppressive therapy such as corticosteroids<sup><xref ref-type="bibr" rid="CR11">11</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. Essentially, these conditions pose a challenge to develop a vaccine for this target population given that the protective immunity may be diminished, together with the fact that the host needs to recognize and fight against different structures of the fungi, such as, conidia, germ tubes, and hyphae. <italic toggle="yes">A. fumigatus</italic> is the most prevalent species of <italic toggle="yes">Aspergillus</italic> responsible for opportunistic human infections, although other species, most commonly <italic toggle="yes">A. flavus</italic>, <italic toggle="yes">A. niger, A. terreus</italic>, and <italic toggle="yes">A. nidulans</italic>, can also cause disease<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>. Invasive aspergillosis is responsible for over 200,000 cases annually and associated with a high mortality rate. Furthermore, allergic manifestations can occur with sensitization to <italic toggle="yes">Aspergillus</italic> allergens, generally in patients with cystic fibrosis, severe asthma with fungal sensitization and allergic bronchopulmonary aspergillosis, the latter alone is thought to affect around 5 million people<sup><xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR63">63</xref></sup>. Therapeutic vaccines to mitigate the allergic response and bias immunity towards protective responses have promise for these difficult to treat diseases, but are still in the early development stage. Another potential <italic toggle="yes">Aspergillus</italic> vaccine market targets avian aspergillosis; outbreaks in commercial poultry flocks, particularly turkeys, can have major economic consequences<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>.</p><p id="Par29">Vaccination studies in mice have demonstrated protection using crude and recombinant <italic toggle="yes">Aspergillus</italic> antigens delivered using a variety of routes and adjuvants (reviewed in the ref. <sup><xref ref-type="bibr" rid="CR65">65</xref></sup>). When examined, protection generally required CD4<sup>+</sup> T cells. Dendritic cells pulsed with conidia or conidial RNA also conferred Th1-mediated antifungal resistance in a mouse model of allogeneic hematopoietic transplantation<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. These studies informed innovative studies in humans undergoing allogenic hematopoietic transplant, where donor T cells can be expanded ex vivo with <italic toggle="yes">Aspergillus</italic> antigens and adoptively transferred into the patient. <italic toggle="yes">Aspergillus</italic>-specific CD4<sup>+</sup> and IFN-&#947;-producing T cell clones, generated by incubating peripheral blood mononuclear cells with heat-killed conidia, were adoptively transferred to transplant recipients with evidence of invasive aspergillosis. Encouragingly, 9 of 10 patients who received adoptive T cells resolved their infection, compared to 7 of 13 control patients who did not receive the immunotherapy<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. A more efficient method for ex vivo expansion of donor T-cell populations using recombinant <italic toggle="yes">A. fumigatus</italic> proteins and selection based on expression of the activation markers CD154 and CD137 has been described<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. Cross-reactivity to other species was observed suggesting this could be part of a broad approach towards therapeutic vaccination in immunocompromised patients with mold infections<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. Another novel approach worthy of mention, although not technically a therapeutic vaccine, is the use of chimeric antigen receptor (CAR) T cells genetically modified for fungal specificity. CAR T cells expressing the &#946;-1,3-glucan receptor Dectin-1 bound to and inhibited <italic toggle="yes">A. fumigatus</italic><sup><xref ref-type="bibr" rid="CR69">69</xref></sup>.</p><p id="Par30">The above studies looked at vaccines that protected largely by eliciting T cell-mediated immunity. Surprisingly, few studies have focused on vaccines designed to elicit protective antibodies. That this approach has merit is suggested by studies showing extended survival of mice that received passive administration of monoclonal antibodies directed to cell surface antigens of <italic toggle="yes">A. fumigatus</italic><sup><xref ref-type="bibr" rid="CR65">65</xref>,<xref ref-type="bibr" rid="CR70">70</xref></sup>. In accordance, exploiting an observation that some sialylated oligosaccharide structures are present in both group B <italic toggle="yes">Streptococcus</italic> (GBS) and <italic toggle="yes">A. fumigatus</italic>, passive transfer of a GBS-specific monoclonal antibodies, and vaccination with GBS improved survival in mouse models of invasive aspergillosis<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>.</p></sec><sec id="Sec9"><title>Endemic mycoses</title><p id="Par31">Endemic mycoses are caused by dimorphic fungi of the Ascomycota phylum, including species of <italic toggle="yes">Histoplasma</italic>, <italic toggle="yes">Coccidioides</italic>, <italic toggle="yes">Blastomyces</italic>, <italic toggle="yes">Paracoccidioides</italic>, <italic toggle="yes">Talaromyces</italic>, and <italic toggle="yes">Emergomyces</italic>. After infectious spores encounter mammalian hosts, temperature-induced phase transition to tissue-invasive yeasts, or for <italic toggle="yes">Coccidioides</italic>, spherules, occurs<sup><xref ref-type="bibr" rid="CR72">72</xref></sup>. Three factors make the endemic mycoses attractive candidates for vaccine development. First, they cause significant morbidity in apparently immunocompetent individuals. Second, a vaccine could be targeted to those at risk due to residence in or travel to the geographic areas where the mycosis is found. Third, the causative fungi are genetically related which increases the feasibility of developing cross-protective vaccines.</p><p id="Par32">A formalin-killed spherule (FKS) vaccine for coccidioidomycosis was studied in a human clinical trial after it showed promising results in mice and Rhesus monkeys. A Phase 3 study randomized 2867 healthy volunteers from California and Arizona; groups received three intramuscular injections of either FKS vaccine or sterile NaCl solution. Unfortunately, no significant differences were observed between groups in terms of clinical endpoints, and the vaccinated groups had greater local and systemic adverse reactions<sup><xref ref-type="bibr" rid="CR73">73</xref></sup>. Nevertheless, the study demonstrated the feasibility of conducting human trials of fungal vaccines. In the field of veterinary medicine, a genetically engineered live-attenuated strain of <italic toggle="yes">B. dermatitidis</italic>, lacking the major virulence factor BAD-1, was safe, well-tolerated, and immunogenic in dogs<sup><xref ref-type="bibr" rid="CR74">74</xref></sup>. Studies to determine vaccine efficacy in canine blastomycosis are still needed, although in experimental models, the vaccine did protect mice from lethal infection.</p><p id="Par33">Given their theoretical safety advantages, identification of protective antigens for use in subunit vaccines has been the focus of much research. One of the earliest candidate antigens identified was heat shock protein (Hsp) 60. Vaccination with recombinant Hsp60 induced protective immunity against <italic toggle="yes">Histoplasma</italic> and <italic toggle="yes">Paracoccidioides</italic> following pulmonary infection in mice<sup><xref ref-type="bibr" rid="CR75">75</xref>,<xref ref-type="bibr" rid="CR76">76</xref></sup>. Fungal and mammalian Hsp are evolutionarily conserved; this raises theoretical concerns about untoward autoimmune responses unless homologous regions are edited out. Other recombinant antigens, many of which have no significant human homologies, have protected mice in experimental models of endemic mycoses<sup><xref ref-type="bibr" rid="CR77">77</xref>&#8211;<xref ref-type="bibr" rid="CR79">79</xref></sup>. A multivalent vaccine containing three recombinant antigens elicited protective responses in mice challenged with <italic toggle="yes">Coccidioides</italic><sup><xref ref-type="bibr" rid="CR80">80</xref></sup>. Moreover, when the peptides of these proteins that elicited the best T cell responses were combined into a recombinant epitope-based vaccine, enhanced survival, reduced fungal burden, and robust Th1 and Th17 immune responses were observed<sup><xref ref-type="bibr" rid="CR81">81</xref></sup>. Use of chimeric proteins reduces the expense of manufacturing and testing vaccines, but could generate unwanted immune responses to the created neoantigens.</p></sec><sec id="Sec10"><title>Pan-fungal vaccines</title><p id="Par34">The above vaccine strategies are mainly focused on preventing specific mycoses. The &#8220;holy grail&#8221; is a pan-fungal vaccine that protects against many if not most of the broad range of systemic fungal infections seen in the human population. In this regard, several vaccine candidates are worthy of mention. As noted above, nearly all medically important fungi possess a cell wall that contains &#946;-glucans. Immunization of mice with &#946;-glucans conjugated to the carrier protein CRM197 resulted in protection against challenge with taxonomically distant fungal pathogens, including <italic toggle="yes">C. albicans</italic>, <italic toggle="yes">A. fumigatus</italic>, and <italic toggle="yes">C. neoformans</italic><sup><xref ref-type="bibr" rid="CR82">82</xref>,<xref ref-type="bibr" rid="CR83">83</xref></sup>. Protection was correlated with an antibody response directed against &#946;-1,3-glucan, but not &#946;-1,6-glucan<sup><xref ref-type="bibr" rid="CR84">84</xref></sup>. Similarly, mice given a subcutaneous inoculation containing whole heat-killed <italic toggle="yes">Saccharomyces cerevisiae</italic> yeast cells were protected against a subsequent challenge with fungi from five genera; the mechanism is uncertain but postulated to require T-cell adaptive responses<sup><xref ref-type="bibr" rid="CR85">85</xref>,<xref ref-type="bibr" rid="CR86">86</xref></sup>. Mice vaccinated with the aforementioned <italic toggle="yes">C. neoformans</italic> strain deleted of the F-box protein Fbp1<sup><xref ref-type="bibr" rid="CR59">59</xref></sup> are cross-protected against <italic toggle="yes">C. gattii</italic>, <italic toggle="yes">Aspergillus fumigatus</italic>, and <italic toggle="yes">Candida albicans</italic>, suggesting its potential to act as a pan-fungal vaccine<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>.</p><p id="Par35">Interestingly, &#946;-glucans are strong stimulators of &#8220;trained immunity&#8221;, a process whereby activation of innate immunity leads to epigenetic changes that enhance responses to subsequent infections<sup><xref ref-type="bibr" rid="CR87">87</xref></sup>. The contribution of trained immunity to the cross-protection seen with pan-fungal vaccines which contain &#946;-glucans merits further study.</p><p id="Par36">The chaperone protein calnexin contains a 13-amino acid sequence which is highly conserved among fungi of the <italic toggle="yes">Ascomycota</italic>, a phylum that contains many medically important fungi including <italic toggle="yes">Aspergillus</italic> and the endemic dimorphic fungi. Vaccine delivery of calnexin in glucan particles conferred immunity to lethal challenge with multiple ascomycetes via expansion of antigen-specific CD4<sup>+</sup> T cells<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>. These results suggest a strategy whereby T or B cell epitopes common to multiple species of fungi could be identified and combined to yield pan-fungal vaccines.</p></sec></sec><sec id="Sec11" sec-type="conclusion"><title>Conclusions</title><p id="Par37">Remarkable progress has been made towards the development of fungal vaccines for use in humans. In animal studies, protection against all the major medically important mycoses has been achieved using a variety of vaccine designs ranging from subunit formulations to live attenuated fungi. Superior efficacy has been demonstrated using novel adjuvants and delivery systems aimed at stimulating arms of the immune system critical for control of fungal invasion. Three vaccines have undergone human trials demonstrating the feasibility of performing clinical trials targeting at risk populations. While many scientific and logistical obstacles remain, there is reason to be optimistic that clinically approved fungal vaccines will be forthcoming.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Research in the authors&#8217; lab is supported by National Institutes of Health grants AI025780, AI139615, AI125045 and contract 75N93019C0004.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>L.V.N.O., R.W., C.A.S., and S.M.L. contributed to the design, writing, and critical review of the paper.</p></notes><notes id="FPar1" notes-type="COI-statement"><title>Competing interests</title><p id="Par38">The authors declare no competing interests.</p></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vallabhaneni</surname><given-names>S</given-names></name><name name-style="western"><surname>Mody</surname><given-names>RK</given-names></name><name name-style="western"><surname>Walker</surname><given-names>T</given-names></name><name name-style="western"><surname>Chiller</surname><given-names>T</given-names></name></person-group><article-title>The global burden of fungal diseases</article-title><source>Infect. Dis. Clin.</source><year>2016</year><volume>30</volume><fpage>1</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/j.idc.2015.10.004</pub-id><pub-id pub-id-type="pmid">26739604</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Fungal vaccines, mechanism of actions and immunology: a comprehensive review</article-title><source>Biomed. Pharmacother.</source><year>2019</year><volume>109</volume><fpage>333</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.biopha.2018.10.075</pub-id><pub-id pub-id-type="pmid">30399567</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name><etal/></person-group><article-title>Hidden killers: human fungal infections</article-title><source>Sci. Transl. Med.</source><year>2012</year><volume>4</volume><fpage>165rv113</fpage><lpage>165rv113</lpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3004404</pub-id><pub-id pub-id-type="pmid">23253612</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bongomin</surname><given-names>F</given-names></name><name name-style="western"><surname>Gago</surname><given-names>S</given-names></name><name name-style="western"><surname>Oladele</surname><given-names>RO</given-names></name><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name></person-group><article-title>Global and multi-national prevalence of fungal diseases-estimate precision</article-title><source>J. Fungi</source><year>2017</year><volume>3</volume><fpage>57</fpage><pub-id pub-id-type="doi">10.3390/jof3040057</pub-id><pub-id pub-id-type="pmcid">PMC5753159</pub-id><pub-id pub-id-type="pmid">29371573</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benedict</surname><given-names>K</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>BR</given-names></name><name name-style="western"><surname>Chiller</surname><given-names>T</given-names></name><name name-style="western"><surname>Beer</surname><given-names>KD</given-names></name></person-group><article-title>Estimation of direct healthcare costs of fungal diseases in the United States</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>68</volume><fpage>1791</fpage><lpage>1797</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy776</pub-id><pub-id pub-id-type="pmcid">PMC6409199</pub-id><pub-id pub-id-type="pmid">30204844</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Golenbock</surname><given-names>DT</given-names></name></person-group><article-title>Beyond empiricism: informing vaccine development through innate immunity research</article-title><source>Cell</source><year>2012</year><volume>148</volume><fpage>1284</fpage><lpage>1292</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2012.02.012</pub-id><pub-id pub-id-type="pmid">22424235</pub-id><pub-id pub-id-type="pmcid">PMC3308125</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levine</surname><given-names>MM</given-names></name><name name-style="western"><surname>Sztein</surname><given-names>MB</given-names></name></person-group><article-title>Vaccine development strategies for improving immunization: the role of modern immunology</article-title><source>Nat. Immunol.</source><year>2004</year><volume>5</volume><fpage>460</fpage><lpage>464</lpage><pub-id pub-id-type="doi">10.1038/ni0504-460</pub-id><pub-id pub-id-type="pmid">15116108</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>K</given-names></name><name name-style="western"><surname>Yanagihara</surname><given-names>N</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>K</given-names></name><name name-style="western"><surname>Miyazaki</surname><given-names>Y</given-names></name></person-group><article-title>Vaccines and protective immune memory against cryptococcosis</article-title><source>Biol. Pharm. Bull.</source><year>2020</year><volume>43</volume><fpage>230</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1248/bpb.b19-00841</pub-id><pub-id pub-id-type="pmid">32009111</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tso</surname><given-names>GHW</given-names></name><name name-style="western"><surname>Reales-Calderon</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pavelka</surname><given-names>N</given-names></name></person-group><article-title>The elusive anti-Candida vaccine: lessons from the past and opportunities for the future</article-title><source>Front. Immunol.</source><year>2018</year><volume>9</volume><fpage>897</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.3389/fimmu.2018.00897</pub-id><pub-id pub-id-type="pmid">29755472</pub-id><pub-id pub-id-type="pmcid">PMC5934487</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caballero Van Dyke</surname><given-names>MC</given-names></name><name name-style="western"><surname>Wormley</surname><given-names>FL</given-names><suffix>Jr.</suffix></name></person-group><article-title>A call to arms: quest for a Cryptococcal vaccine</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>436</fpage><lpage>446</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2017.10.002</pub-id><pub-id pub-id-type="pmid">29103990</pub-id><pub-id pub-id-type="pmcid">PMC5910246</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Aspergillus vaccines: Hardly worth studying or worthy of hard study?</article-title><source>Med. Mycol.</source><year>2017</year><volume>55</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1093/mmy/myw081</pub-id><pub-id pub-id-type="pmid">27639242</pub-id><pub-id pub-id-type="pmcid">PMC5166590</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ljungman</surname><given-names>P</given-names></name></person-group><article-title>Vaccination of immunocompromised patients</article-title><source>Clin. Microbiol. Infect.</source><year>2012</year><volume>18</volume><fpage>93</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1111/j.1469-0691.2012.03971.x</pub-id><pub-id pub-id-type="pmid">23051059</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mestas</surname><given-names>J</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>CCW</given-names></name></person-group><article-title>Of mice and not men: differences between mouse and human immunology</article-title><source>J. Immunol.</source><year>2004</year><volume>172</volume><fpage>2731</fpage><lpage>2738</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.172.5.2731</pub-id><pub-id pub-id-type="pmid">14978070</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herv&#233;</surname><given-names>C</given-names></name><name name-style="western"><surname>Laup&#232;ze</surname><given-names>B</given-names></name><name name-style="western"><surname>Del Giudice</surname><given-names>G</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>AM</given-names></name><name name-style="western"><surname>Tavares Da Silva</surname><given-names>F</given-names></name></person-group><article-title>The how&#8217;s and what&#8217;s of vaccine reactogenicity</article-title><source>npj Vaccines</source><year>2019</year><volume>4</volume><fpage>39</fpage><pub-id pub-id-type="doi">10.1038/s41541-019-0132-6</pub-id><pub-id pub-id-type="pmid">31583123</pub-id><pub-id pub-id-type="pmcid">PMC6760227</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burki</surname><given-names>F</given-names></name></person-group><article-title>The eukaryotic tree of life from a global phylogenomic perspective</article-title><source>Cold Spring Harb. Perspect. Biol.</source><year>2014</year><volume>6</volume><fpage>a016147</fpage><lpage>a016147</lpage><pub-id pub-id-type="doi">10.1101/cshperspect.a016147</pub-id><pub-id pub-id-type="pmid">24789819</pub-id><pub-id pub-id-type="pmcid">PMC3996474</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>CC</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Fungal immunology in clinical practice: magical realism or practical reality?</article-title><source>Med. Mycol.</source><year>2019</year><volume>57</volume><fpage>S294</fpage><lpage>S306</lpage><pub-id pub-id-type="doi">10.1093/mmy/myy165</pub-id><pub-id pub-id-type="pmid">31292656</pub-id><pub-id pub-id-type="pmcid">PMC7137463</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Garcia-Rubio, R., de Oliveira, H. C., Rivera, J. &amp; Trevijano-Contador, N. The fungal cell wall: Candida, Cryptococcus, and Aspergillus species. <italic toggle="yes">Front. Microbiol.</italic>10.3389/fmicb.2019.02993 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2019.02993</pub-id><pub-id pub-id-type="pmcid">PMC6962315</pub-id><pub-id pub-id-type="pmid">31993032</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ostroff</surname><given-names>GR</given-names></name><name name-style="western"><surname>Specht</surname><given-names>CA</given-names></name></person-group><article-title>Exploiting fungal cell wall components in vaccines</article-title><source>Semin. Immunopathol.</source><year>2015</year><volume>37</volume><fpage>199</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1007/s00281-014-0460-6</pub-id><pub-id pub-id-type="pmid">25404118</pub-id><pub-id pub-id-type="pmcid">PMC4329074</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drummond</surname><given-names>RA</given-names></name><name name-style="western"><surname>Gaffen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Hise</surname><given-names>AG</given-names></name><name name-style="western"><surname>Brown</surname><given-names>GD</given-names></name></person-group><article-title>Innate defense against fungal pathogens</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2014</year><volume>5</volume><fpage>a019620</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a019620</pub-id><pub-id pub-id-type="pmid">25384766</pub-id><pub-id pub-id-type="pmcid">PMC4426252</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patin</surname><given-names>EC</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A</given-names></name><name name-style="western"><surname>Orr</surname><given-names>SJ</given-names></name></person-group><article-title>Pattern recognition receptors in fungal immunity</article-title><source>Semin. Cell Dev. Biol.</source><year>2019</year><volume>89</volume><fpage>24</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1016/j.semcdb.2018.03.003</pub-id><pub-id pub-id-type="pmid">29522806</pub-id><pub-id pub-id-type="pmcid">PMC6461132</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Gow, N. A. R., Latge, J. P. &amp; Munro, C. A. The fungal cell wall: structure, biosynthesis, and function. <italic toggle="yes">Microbiol. Spectr.</italic>10.1128/microbiolspec.FUNK-0035-2016 (2017).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/microbiolspec.funk-0035-2016</pub-id><pub-id pub-id-type="pmcid">PMC11687499</pub-id><pub-id pub-id-type="pmid">28513415</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name><etal/></person-group><article-title>The capsule of Cryptococcus neoformans</article-title><source>Virulence</source><year>2019</year><volume>10</volume><fpage>822</fpage><lpage>831</lpage><pub-id pub-id-type="doi">10.1080/21505594.2018.1431087</pub-id><pub-id pub-id-type="pmid">29436899</pub-id><pub-id pub-id-type="pmcid">PMC6779390</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bielska</surname><given-names>E</given-names></name><name name-style="western"><surname>May</surname><given-names>RC</given-names></name></person-group><article-title>Extracellular vesicles of human pathogenic fungi</article-title><source>Curr. Opin. Microbiol.</source><year>2019</year><volume>52</volume><fpage>90</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2019.05.007</pub-id><pub-id pub-id-type="pmid">31280026</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hopke</surname><given-names>A</given-names></name><name name-style="western"><surname>Brown</surname><given-names>AJP</given-names></name><name name-style="western"><surname>Hall</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wheeler</surname><given-names>RT</given-names></name></person-group><article-title>Dynamic fungal cell wall architecture in stress adaptation and immune evasion</article-title><source>Trends Microbiol.</source><year>2018</year><volume>26</volume><fpage>284</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2018.01.007</pub-id><pub-id pub-id-type="pmid">29452950</pub-id><pub-id pub-id-type="pmcid">PMC5869159</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>K</given-names></name><etal/></person-group><article-title>A dendritic cell-based systemic vaccine induces long-lived lung-resident memory Th17 cells and ameliorates pulmonary mycosis</article-title><source>Mucosal Immunol.</source><year>2019</year><volume>12</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1038/s41385-018-0094-4</pub-id><pub-id pub-id-type="pmid">30279512</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lionakis</surname><given-names>MS</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Host control of fungal infections: lessons from basic studies and human cohorts</article-title><source>Annu. Rev. Immunol.</source><year>2018</year><volume>36</volume><fpage>157</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042617-053318</pub-id><pub-id pub-id-type="pmid">29237128</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Portuondo</surname><given-names>DL</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>LS</given-names></name><name name-style="western"><surname>Urbaczek</surname><given-names>AC</given-names></name><name name-style="western"><surname>Batista-Duharte</surname><given-names>A</given-names></name><name name-style="western"><surname>Carlos</surname><given-names>IZ</given-names></name></person-group><article-title>Adjuvants and delivery systems for antifungal vaccines: current state and future developments</article-title><source>Med. Mycol.</source><year>2015</year><volume>53</volume><fpage>69</fpage><lpage>89</lpage><pub-id pub-id-type="doi">10.1093/mmy/myu045</pub-id><pub-id pub-id-type="pmid">25362733</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><name name-style="western"><surname>Ostroff</surname><given-names>GR</given-names></name><name name-style="western"><surname>Lee</surname><given-names>CK</given-names></name><name name-style="western"><surname>Specht</surname><given-names>CA</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Characterization and optimization of the glucan particle-based vaccine platform</article-title><source>Clin. Vaccin. Immunol.</source><year>2013</year><volume>20</volume><fpage>1585</fpage><lpage>1591</lpage><pub-id pub-id-type="doi">10.1128/CVI.00463-13</pub-id><pub-id pub-id-type="pmcid">PMC3807193</pub-id><pub-id pub-id-type="pmid">23945157</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Relative contributions of dectin-1 and complement to immune responses to particulate beta-glucans</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>312</fpage><lpage>317</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200603</pub-id><pub-id pub-id-type="pmid">22649195</pub-id><pub-id pub-id-type="pmcid">PMC3381926</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Deepe</surname><given-names>GS</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Vaccination with an alkaline extract of Histoplasma capsulatum packaged in glucan particles confers protective immunity in mice</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>3359</fpage><lpage>3367</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.04.047</pub-id><pub-id pub-id-type="pmid">29729993</pub-id><pub-id pub-id-type="pmcid">PMC5960637</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hester</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>620</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.10.051</pub-id><pub-id pub-id-type="pmid">31699504</pub-id><pub-id pub-id-type="pmcid">PMC6954324</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Specht</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Vaccination with recombinant Cryptococcus proteins in glucan particles protects mice against cryptococcosis in a manner dependent upon mouse strain and cryptococcal species</article-title><source>mBio</source><year>2017</year><volume>8</volume><fpage>e01872</fpage><lpage>01817</lpage><pub-id pub-id-type="doi">10.1128/mBio.01872-17</pub-id><pub-id pub-id-type="pmid">29184017</pub-id><pub-id pub-id-type="pmcid">PMC5705919</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wuthrich</surname><given-names>M</given-names></name><etal/></person-group><article-title>Calnexin induces expansion of antigen-specific CD4<sup>+</sup> T cells that confer immunity to fungal ascomycetes via conserved epitopes</article-title><source>Cell Host Microbe</source><year>2015</year><volume>17</volume><fpage>452</fpage><lpage>465</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.02.009</pub-id><pub-id pub-id-type="pmid">25800545</pub-id><pub-id pub-id-type="pmcid">PMC4484745</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Hung, C. Y. et al. Glucan-chitin particles enhance Th17 response and improve protective efficacy of a multivalent antigen (rCpa1) against pulmonary Coccidioides posadasii infection. <italic toggle="yes">Infect. Immun.</italic>10.1128/IAI.00070-18 (2018).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/IAI.00070-18</pub-id><pub-id pub-id-type="pmcid">PMC6204714</pub-id><pub-id pub-id-type="pmid">30104216</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Herwald</surname><given-names>SE</given-names></name><name name-style="western"><surname>Kumamoto</surname><given-names>CA</given-names></name></person-group><article-title>Candida albicans niche specialization: features that distinguish biofilm cells from commensal cells</article-title><source>Curr. Fungal Infect. Rep.</source><year>2014</year><volume>8</volume><fpage>179</fpage><lpage>184</lpage><pub-id pub-id-type="doi">10.1007/s12281-014-0178-x</pub-id><pub-id pub-id-type="pmid">24839528</pub-id><pub-id pub-id-type="pmcid">PMC4019406</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denning</surname><given-names>DW</given-names></name><name name-style="western"><surname>Kneale</surname><given-names>M</given-names></name><name name-style="western"><surname>Sobel</surname><given-names>JD</given-names></name><name name-style="western"><surname>Rautemaa-Richardson</surname><given-names>R</given-names></name></person-group><article-title>Global burden of recurrent vulvovaginal candidiasis: a systematic review</article-title><source>Lancet Infect. Dis.</source><year>2018</year><volume>18</volume><fpage>e339</fpage><lpage>e347</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(18)30103-8</pub-id><pub-id pub-id-type="pmid">30078662</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>YL</given-names></name><etal/></person-group><article-title>Non-lethal Candida albicans cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells</article-title><source>Mycol. Res.</source><year>2009</year><volume>113</volume><fpage>388</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1016/j.mycres.2008.11.016</pub-id><pub-id pub-id-type="pmid">19111931</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><name name-style="western"><surname>Graziani</surname><given-names>S</given-names></name><name name-style="western"><surname>Tirelli</surname><given-names>F</given-names></name><name name-style="western"><surname>Antonopoulou</surname><given-names>S</given-names></name></person-group><article-title>Candida vaginitis: virulence, host response and vaccine prospects</article-title><source>Med. Mycol.</source><year>2018</year><volume>56</volume><fpage>S26</fpage><lpage>S31</lpage><pub-id pub-id-type="doi">10.1093/mmy/myx139</pub-id><pub-id pub-id-type="pmid">29538739</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schmidt</surname><given-names>CS</given-names></name><etal/></person-group><article-title>NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>7594</fpage><lpage>7600</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.10.038</pub-id><pub-id pub-id-type="pmid">23099329</pub-id><pub-id pub-id-type="pmcid">PMC3513491</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vargas</surname><given-names>G</given-names></name><etal/></person-group><article-title>Protective effect of fungal extracellular vesicles against murine candidiasis</article-title><source>Cell Microbiol.</source><year>2020</year><volume>22</volume><fpage>e13238</fpage><pub-id pub-id-type="doi">10.1111/cmi.13238</pub-id><pub-id pub-id-type="pmid">32558196</pub-id><pub-id pub-id-type="pmcid">PMC7499402</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xin</surname><given-names>H</given-names></name><name name-style="western"><surname>Dziadek</surname><given-names>S</given-names></name><name name-style="western"><surname>Bundle</surname><given-names>DR</given-names></name><name name-style="western"><surname>Cutler</surname><given-names>JE</given-names></name></person-group><article-title>Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2008</year><volume>105</volume><fpage>13526</fpage><lpage>13531</lpage><pub-id pub-id-type="doi">10.1073/pnas.0803195105</pub-id><pub-id pub-id-type="pmid">18725625</pub-id><pub-id pub-id-type="pmcid">PMC2533223</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Bernardis</surname><given-names>F</given-names></name><etal/></person-group><article-title>A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4490</fpage><lpage>4498</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.069</pub-id><pub-id pub-id-type="pmid">22561143</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>A fungal immunotherapeutic vaccine (NDV-3a) for treatment of recurrent vulvovaginal candidiasis&#8212;a phase 2 randomized, double-blind, placebo-controlled trial</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>1928</fpage><lpage>1936</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy185</pub-id><pub-id pub-id-type="pmid">29697768</pub-id><pub-id pub-id-type="pmcid">PMC5982716</pub-id></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casadevall</surname><given-names>A</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L-A</given-names></name></person-group><article-title>A therapeutic vaccine for recurrent vulvovaginal candidiasis</article-title><source>Clin. Infect. Dis.</source><year>2018</year><volume>66</volume><fpage>1937</fpage><lpage>1939</lpage><pub-id pub-id-type="doi">10.1093/cid/ciy188</pub-id><pub-id pub-id-type="pmid">29697770</pub-id><pub-id pub-id-type="pmcid">PMC9989336</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cassone</surname><given-names>A</given-names></name></person-group><article-title>Development of vaccines for <italic toggle="yes">Candida albicans</italic>: fighting a skilled transformer</article-title><source>Nat. Rev. Microbiol.</source><year>2013</year><volume>11</volume><fpage>884</fpage><lpage>891</lpage><pub-id pub-id-type="doi">10.1038/nrmicro3156</pub-id><pub-id pub-id-type="pmid">24232568</pub-id></element-citation></ref><ref id="CR46"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarang</surname><given-names>S</given-names></name><etal/></person-group><article-title>In silico design of a multivalent vaccine against <italic toggle="yes">Candida albicans</italic></article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>1066</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-57906-x</pub-id><pub-id pub-id-type="pmid">31974431</pub-id><pub-id pub-id-type="pmcid">PMC6978452</pub-id></element-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rajasingham</surname><given-names>R</given-names></name><etal/></person-group><article-title>Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis</article-title><source>Lancet Infect. Dis.</source><year>2017</year><volume>17</volume><fpage>873</fpage><lpage>881</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(17)30243-8</pub-id><pub-id pub-id-type="pmid">28483415</pub-id><pub-id pub-id-type="pmcid">PMC5818156</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Devi</surname><given-names>SJN</given-names></name></person-group><article-title>Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model</article-title><source>Vaccine</source><year>1996</year><volume>14</volume><fpage>841</fpage><lpage>844</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(95)00256-Z</pub-id><pub-id pub-id-type="pmid">8843625</pub-id></element-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Datta</surname><given-names>K</given-names></name><name name-style="western"><surname>Lees</surname><given-names>A</given-names></name><name name-style="western"><surname>Pirofski</surname><given-names>L-a</given-names></name></person-group><article-title>Therapeutic efficacy of a conjugate vaccine containing a peptide mimotope of cryptococcal capsular polysaccharide glucuronoxylomannan</article-title><source>Clin. Vaccin. Immunol.</source><year>2008</year><volume>15</volume><fpage>1176</fpage><lpage>1187</lpage><pub-id pub-id-type="doi">10.1128/CVI.00130-08</pub-id><pub-id pub-id-type="pmcid">PMC2519304</pub-id><pub-id pub-id-type="pmid">18524882</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mansour</surname><given-names>MK</given-names></name><name name-style="western"><surname>Yauch</surname><given-names>LE</given-names></name><name name-style="western"><surname>Rottman</surname><given-names>JB</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Protective efficacy of antigenic fractions in mouse models of cryptococcosis</article-title><source>Infect. Immun.</source><year>2004</year><volume>72</volume><fpage>1746</fpage><lpage>1754</lpage><pub-id pub-id-type="doi">10.1128/IAI.72.3.1746-1754.2004</pub-id><pub-id pub-id-type="pmid">14977983</pub-id><pub-id pub-id-type="pmcid">PMC356047</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Weintraub</surname><given-names>ST</given-names></name><name name-style="western"><surname>Lopez-Ribot</surname><given-names>JL</given-names></name><name name-style="western"><surname>Wormley</surname><given-names>FL</given-names><suffix>Jr.</suffix></name></person-group><article-title>Identification and characterization of Cryptococcus neoformans protein fractions that induce protective immune responses</article-title><source>Proteomics</source><year>2013</year><volume>13</volume><fpage>3429</fpage><lpage>3441</lpage><pub-id pub-id-type="doi">10.1002/pmic.201300213</pub-id><pub-id pub-id-type="pmid">24170628</pub-id><pub-id pub-id-type="pmcid">PMC3916089</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Specht</surname><given-names>CA</given-names></name><etal/></person-group><article-title>Protection against experimental cryptococcosis following vaccination with glucan particles containing cryptococcus alkaline extracts</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e01905</fpage><lpage>e01915</lpage><pub-id pub-id-type="doi">10.1128/mBio.01905-15</pub-id><pub-id pub-id-type="pmid">26695631</pub-id><pub-id pub-id-type="pmcid">PMC4701832</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>AK</given-names></name><etal/></person-group><article-title>Vaccine-mediated immune responses to experimental pulmonary Cryptococcus gattii infection in mice</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><fpage>e104316</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0104316</pub-id><pub-id pub-id-type="pmid">25119981</pub-id><pub-id pub-id-type="pmcid">PMC4132117</pub-id></element-citation></ref><ref id="CR54"><label>54.</label><mixed-citation publication-type="other">Rizzo, J. et al. New insights into Cryptococcus extracellular vesicles suggest a new structural model and an antifungal vaccine strategy. Preprint at <italic toggle="yes">bioRxiv</italic>10.1101/2020.08.17.253716 (2020).</mixed-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Hester, M. M. et al. Protection of mice against experimental cryptococcosis using glucan particle-based vaccines containing novel recombinant antigens. <italic toggle="yes">Vaccine</italic>10.1016/j.vaccine.2019.10.051 (2019).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2019.10.051</pub-id><pub-id pub-id-type="pmcid">PMC6954324</pub-id><pub-id pub-id-type="pmid">31699504</pub-id></mixed-citation></ref><ref id="CR56"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Upadhya</surname><given-names>R</given-names></name><etal/></person-group><article-title>Induction of protective immunity to cryptococcal infection in mice by a heat-killed, chitosan-deficient strain of Cryptococcus neoformans</article-title><source>mBio</source><year>2016</year><volume>7</volume><fpage>e00547</fpage><lpage>00516</lpage><pub-id pub-id-type="doi">10.1128/mBio.00547-16</pub-id><pub-id pub-id-type="pmid">27165801</pub-id><pub-id pub-id-type="pmcid">PMC4959652</pub-id></element-citation></ref><ref id="CR57"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhai</surname><given-names>B</given-names></name><etal/></person-group><article-title>Development of protective inflammation and cell-mediated immunity against Cryptococcus neoformans after exposure to hyphal mutants</article-title><source>mBio</source><year>2015</year><volume>6</volume><fpage>e01433</fpage><lpage>01415</lpage><pub-id pub-id-type="doi">10.1128/mBio.01433-15</pub-id><pub-id pub-id-type="pmid">26443458</pub-id><pub-id pub-id-type="pmcid">PMC4611043</pub-id></element-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Rella, A. et al. Role of sterylglucosidase 1 (Sgl1) on the pathogenicity of Cryptococcus neoformans: potential applications for vaccine development. <italic toggle="yes">Front. Microbiol.</italic>10.3389/fmicb.2015.00836 (2015).<pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fmicb.2015.00836</pub-id><pub-id pub-id-type="pmcid">PMC4531891</pub-id><pub-id pub-id-type="pmid">26322039</pub-id></mixed-citation></ref><ref id="CR59"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K</given-names></name><name name-style="western"><surname>Masso-Silva</surname><given-names>JA</given-names></name><name name-style="western"><surname>Rivera</surname><given-names>A</given-names></name><name name-style="western"><surname>Xue</surname><given-names>C</given-names></name></person-group><article-title>A heat-killed Cryptococcus mutant strain induces host protection against multiple invasive mycoses in a murine vaccine model</article-title><source>mBio</source><year>2019</year><volume>10</volume><fpage>e02145</fpage><lpage>02119</lpage><pub-id pub-id-type="pmid">31772051</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/mBio.02145-19</pub-id><pub-id pub-id-type="pmcid">PMC6879717</pub-id></element-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wormley</surname><given-names>FL</given-names></name><name name-style="western"><surname>Perfect</surname><given-names>JR</given-names></name><name name-style="western"><surname>Steele</surname><given-names>C</given-names></name><name name-style="western"><surname>Cox</surname><given-names>GM</given-names></name></person-group><article-title>Protection against cryptococcosis by using a murine gamma interferon-producing Cryptococcus neoformans strain</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>1453</fpage><pub-id pub-id-type="doi">10.1128/IAI.00274-06</pub-id><pub-id pub-id-type="pmid">17210668</pub-id><pub-id pub-id-type="pmcid">PMC1828544</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hole</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Induction of memory-like dendritic cell responses in vivo</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>2955</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-10486-5</pub-id><pub-id pub-id-type="pmid">31273203</pub-id><pub-id pub-id-type="pmcid">PMC6609631</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Angkasekwinai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Cryptococcus gattii infection dampens Th1 and Th17 responses by attenuating dendritic cell function and pulmonary chemokine expression in the immunocompetent hosts</article-title><source>Infect. Immun.</source><year>2014</year><volume>82</volume><fpage>3880</fpage><lpage>3890</lpage><pub-id pub-id-type="doi">10.1128/IAI.01773-14</pub-id><pub-id pub-id-type="pmid">24980974</pub-id><pub-id pub-id-type="pmcid">PMC4187835</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van de Veerdonk</surname><given-names>FL</given-names></name><name name-style="western"><surname>Gresnigt</surname><given-names>MS</given-names></name><name name-style="western"><surname>Romani</surname><given-names>L</given-names></name><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><name name-style="western"><surname>Latg&#233;</surname><given-names>J-P</given-names></name></person-group><article-title>Aspergillus fumigatus morphology and dynamic host interactions</article-title><source>Nat. Rev. Microbiol.</source><year>2017</year><volume>15</volume><fpage>661</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1038/nrmicro.2017.90</pub-id><pub-id pub-id-type="pmid">28919635</pub-id></element-citation></ref><ref id="CR64"><label>64.</label><mixed-citation publication-type="other">Vahsen, T. et al. Cellular and molecular insights on the regulation of innate immune responses to experimental aspergillosis in chicken and turkey poults. <italic toggle="yes">Med. Mycol.</italic>10.1093/mmy/myaa069 (2020).<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/mmy/myaa069</pub-id><pub-id pub-id-type="pmid">32844181</pub-id></mixed-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name></person-group><article-title>Aspergillus vaccines: Hardly worth studying or worthy of hard study?</article-title><source>Med. Mycol.</source><year>2017</year><volume>55</volume><fpage>103</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1093/mmy/myw081</pub-id><pub-id pub-id-type="pmid">27639242</pub-id><pub-id pub-id-type="pmcid">PMC5166590</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozza</surname><given-names>S</given-names></name><etal/></person-group><article-title>A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation</article-title><source>Blood</source><year>2003</year><volume>102</volume><fpage>3807</fpage><lpage>3814</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-03-0748</pub-id><pub-id pub-id-type="pmid">12791648</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perruccio</surname><given-names>K</given-names></name><etal/></person-group><article-title>Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation</article-title><source>Blood</source><year>2005</year><volume>106</volume><fpage>4397</fpage><lpage>4406</lpage><pub-id pub-id-type="doi">10.1182/blood-2005-05-1775</pub-id><pub-id pub-id-type="pmid">16123217</pub-id><pub-id pub-id-type="pmcid">PMC1895249</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stuehler</surname><given-names>C</given-names></name><etal/></person-group><article-title>Multispecific aspergillus T cells selected by CD137 or CD154 induce protective immune responses against the most relevant mold infections</article-title><source>J. Infect. Dis.</source><year>2015</year><volume>211</volume><fpage>1251</fpage><lpage>1261</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu607</pub-id><pub-id pub-id-type="pmid">25367298</pub-id></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumaresan</surname><given-names>PR</given-names></name><etal/></person-group><article-title>Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2014</year><volume>111</volume><fpage>10660</fpage><lpage>10665</lpage><pub-id pub-id-type="doi">10.1073/pnas.1312789111</pub-id><pub-id pub-id-type="pmid">25002471</pub-id><pub-id pub-id-type="pmcid">PMC4115509</pub-id></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chaturvedi</surname><given-names>AK</given-names></name><name name-style="western"><surname>Kavishwar</surname><given-names>A</given-names></name><name name-style="western"><surname>Shiva Keshava</surname><given-names>GB</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>PK</given-names></name></person-group><article-title>Monoclonal immunoglobulin G1 Directed against Aspergillus fumigatus cell wall glycoprotein Protects against experimental murine aspergillosis</article-title><source>Clin. Diagn. Lab. Immunol.</source><year>2005</year><volume>12</volume><fpage>1063</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1128/CDLI.12.9.1063-1068.2005</pub-id><pub-id pub-id-type="pmid">16148172</pub-id><pub-id pub-id-type="pmcid">PMC1235786</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wharton</surname><given-names>RE</given-names></name><name name-style="western"><surname>Stefanov</surname><given-names>EK</given-names></name><name name-style="western"><surname>King</surname><given-names>RG</given-names></name><name name-style="western"><surname>Kearney</surname><given-names>JF</given-names></name></person-group><article-title>Antibodies generated against streptococci protect in a mouse model of disseminated aspergillosis</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>4387</fpage><pub-id pub-id-type="doi">10.4049/jimmunol.1401940</pub-id><pub-id pub-id-type="pmid">25821219</pub-id><pub-id pub-id-type="pmcid">PMC4402265</pub-id></element-citation></ref><ref id="CR72"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klein</surname><given-names>BS</given-names></name><name name-style="western"><surname>Tebbets</surname><given-names>B</given-names></name></person-group><article-title>Dimorphism and virulence in fungi</article-title><source>Curr. Opin. Microbiol.</source><year>2007</year><volume>10</volume><fpage>314</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1016/j.mib.2007.04.002</pub-id><pub-id pub-id-type="pmid">17719267</pub-id><pub-id pub-id-type="pmcid">PMC3412142</pub-id></element-citation></ref><ref id="CR73"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pappagianis</surname><given-names>D</given-names></name></person-group><article-title>Evaluation of the protective efficacy of the killed Coccidioides immitis spherule vaccine in humans. The Valley Fever Vaccine Study Group</article-title><source>Am. Rev. Respir. Dis.</source><year>1993</year><volume>148</volume><fpage>656</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1164/ajrccm/148.3.656</pub-id><pub-id pub-id-type="pmid">8368636</pub-id></element-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>W&#252;thrich</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of a recombinant, genetically engineered, live-attenuated vaccine against canine blastomycosis</article-title><source>Clin. Vaccin. Immunol.</source><year>2011</year><volume>18</volume><fpage>783</fpage><lpage>789</lpage><pub-id pub-id-type="doi">10.1128/CVI.00560-10</pub-id><pub-id pub-id-type="pmcid">PMC3122516</pub-id><pub-id pub-id-type="pmid">21367980</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cleare</surname><given-names>LG</given-names></name><name name-style="western"><surname>Zamith-Miranda</surname><given-names>D</given-names></name><name name-style="western"><surname>Nosanchuk</surname><given-names>JD</given-names></name></person-group><article-title>Heat shock proteins in Histoplasma and Paracoccidioides</article-title><source>Clin. Vaccin. Immunol.</source><year>2017</year><volume>24</volume><fpage>e00217</fpage><lpage>00217</lpage><pub-id pub-id-type="doi">10.1128/CVI.00221-17</pub-id><pub-id pub-id-type="pmcid">PMC5674194</pub-id><pub-id pub-id-type="pmid">28903987</pub-id></element-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Bastos Ascenco Soares</surname><given-names>R</given-names></name><name name-style="western"><surname>Gomez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>de Almeida Soares</surname><given-names>CM</given-names></name><name name-style="western"><surname>Deepe</surname><given-names>GS</given-names><suffix>Jr.</suffix></name></person-group><article-title>Vaccination with heat shock protein 60 induces a protective immune response against experimental Paracoccidioides brasiliensis pulmonary infection</article-title><source>Infect. Immun.</source><year>2008</year><volume>76</volume><fpage>4214</fpage><lpage>4221</lpage><pub-id pub-id-type="doi">10.1128/IAI.00753-07</pub-id><pub-id pub-id-type="pmid">18625731</pub-id><pub-id pub-id-type="pmcid">PMC2519447</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Dyke</surname><given-names>MCC</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>GR</given-names></name><name name-style="western"><surname>Galgiani</surname><given-names>JN</given-names></name><name name-style="western"><surname>Barker</surname><given-names>BM</given-names></name></person-group><article-title>The rise of Coccidioides: forces against the dust devil unleashed</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><fpage>2188</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2019.02188</pub-id><pub-id pub-id-type="pmid">31572393</pub-id><pub-id pub-id-type="pmcid">PMC6749157</pub-id></element-citation></ref><ref id="CR78"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Carnero</surname><given-names>LC</given-names></name><name name-style="western"><surname>Perez-Garcia</surname><given-names>LA</given-names></name><name name-style="western"><surname>Martinez-Alvarez</surname><given-names>JA</given-names></name><name name-style="western"><surname>Reyes-Martinez</surname><given-names>JE</given-names></name><name name-style="western"><surname>Mora-Montes</surname><given-names>HM</given-names></name></person-group><article-title>Current trends to control fungal pathogens: exploiting our knowledge in the host-pathogen interaction</article-title><source>Infect. Drug Resist.</source><year>2018</year><volume>11</volume><fpage>903</fpage><lpage>913</lpage><pub-id pub-id-type="doi">10.2147/IDR.S170337</pub-id><pub-id pub-id-type="pmid">30013373</pub-id><pub-id pub-id-type="pmcid">PMC6037146</pub-id></element-citation></ref><ref id="CR79"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>LP</given-names></name><name name-style="western"><surname>Woo</surname><given-names>PC</given-names></name><name name-style="western"><surname>Wu</surname><given-names>AY</given-names></name><name name-style="western"><surname>Yuen</surname><given-names>KY</given-names></name></person-group><article-title>DNA immunization using a secreted cell wall antigen Mp1p is protective against Penicillium marneffei infection</article-title><source>Vaccine</source><year>2002</year><volume>20</volume><fpage>2878</fpage><lpage>2886</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(02)00234-7</pub-id><pub-id pub-id-type="pmid">12126898</pub-id></element-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tarcha</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Basrur</surname><given-names>V</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CY</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Cole</surname><given-names>GT</given-names></name></person-group><article-title>Multivalent recombinant protein vaccine against coccidioidomycosis</article-title><source>Infect. Immun.</source><year>2006</year><volume>74</volume><fpage>5802</fpage><lpage>5813</lpage><pub-id pub-id-type="doi">10.1128/IAI.00961-06</pub-id><pub-id pub-id-type="pmid">16988258</pub-id><pub-id pub-id-type="pmcid">PMC1594896</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hurtgen</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Hung</surname><given-names>CY</given-names></name><name name-style="western"><surname>Ostroff</surname><given-names>GR</given-names></name><name name-style="western"><surname>Levitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Cole</surname><given-names>GT</given-names></name></person-group><article-title>Construction and evaluation of a novel recombinant T cell epitope-based vaccine against coccidioidomycosis</article-title><source>Infect. Immun.</source><year>2012</year><volume>80</volume><fpage>3960</fpage><lpage>3974</lpage><pub-id pub-id-type="doi">10.1128/IAI.00566-12</pub-id><pub-id pub-id-type="pmid">22949556</pub-id><pub-id pub-id-type="pmcid">PMC3486067</pub-id></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rachini</surname><given-names>A</given-names></name><etal/></person-group><article-title>An anti-beta-glucan monoclonal antibody inhibits growth and capsule formation of Cryptococcus neoformans in vitro and exerts therapeutic, anticryptococcal activity in vivo</article-title><source>Infect. Immun.</source><year>2007</year><volume>75</volume><fpage>5085</fpage><lpage>5094</lpage><pub-id pub-id-type="doi">10.1128/IAI.00278-07</pub-id><pub-id pub-id-type="pmid">17606600</pub-id><pub-id pub-id-type="pmcid">PMC2168274</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Torosantucci</surname><given-names>A</given-names></name><etal/></person-group><article-title>A novel glyco-conjugate vaccine against fungal pathogens</article-title><source>J. Exp. Med.</source><year>2005</year><volume>202</volume><fpage>597</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1084/jem.20050749</pub-id><pub-id pub-id-type="pmid">16147975</pub-id><pub-id pub-id-type="pmcid">PMC2212864</pub-id></element-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bromuro</surname><given-names>C</given-names></name><etal/></person-group><article-title>Beta-glucan-CRM197 conjugates as candidates antifungal vaccines</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>2615</fpage><lpage>2623</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.01.012</pub-id><pub-id pub-id-type="pmid">20096763</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clemons</surname><given-names>KV</given-names></name><etal/></person-group><article-title>Whole glucan particles as a vaccine against murine aspergillosis</article-title><source>J. Med. Microbiol.</source><year>2014</year><volume>63</volume><fpage>1750</fpage><lpage>1759</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.079681-0</pub-id><pub-id pub-id-type="pmid">25288643</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>Immune responses induced by heat killed Saccharomyces cerevisiae: a vaccine against fungal infection</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>1745</fpage><lpage>1753</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.12.119</pub-id><pub-id pub-id-type="pmid">21219976</pub-id><pub-id pub-id-type="pmcid">PMC5508752</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>MG</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></element-citation></ref></ref-list></back></article></pmc-articleset>